Purvi S. Parikh, MD, FACP, FACAAI / Cedric ""Jamie"" Rutland, MD - Taking It From the Top: Targeting a New Approach to Controlling Severe Asthma

Go online to PeerView.com/FTN860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. In this activity, experts in asthma detail the
pathophysiology of severe asthma, with a discussion of the
underlying mechanisms behind both type 2 and non–type 2 asthma, and
novel and emerging therapies for its treatment. Upon completion of
this CE activity, participants will be able to: Discuss unmet
treatment needs for patients with severe, uncontrolled asthma,
particularly those who lack an eosinophilic or allergic phenotype,
Explain the role of thymic stromal lymphopoietin (TSLP) as a driver
of eosinophilic, allergic, and neutrophilic inflammation as well as
structural changes to the airway in asthma due to its position at
the top of the inflammatory cascade, Recognize the potential of
targeted therapies that block the activity of epithelial cytokines
such as TSLP for the treatment of severe, uncontrolled asthma,
Identify patients who might be eligible for treatment with
novel/emerging biologic therapies that target epithelial cytokines
such as TSLP.